Original ArticlesECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine PretreatmentChen, Andrew C.-H. M.D., Ph.D.; Shin, Kyung-Ho M.D., Ph.D.; Duman, Ronald S. Ph.D.; Sanacora, Gerard M.D., Ph.D.Author Information Abraham Ribicoff Research Facilities, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, Connecticut, U.S.A. Received January 31, 2000; accepted April 5, 2000. Address correspondence and reprint requests to Dr. G. Sanacora, Abraham Ribicoff Research Facilities, Yale University School of Medicine, Connecticut Mental Health Center, 34 Park St., New Haven, CT 06508, U.S.A. E-mail: [email protected] The Journal of ECT: March 2001 - Volume 17 - Issue 1 - p 27-32 Buy Abstract Recent evidence suggests hippocampal and possibly cortical atrophy is associated with major depression. Chronic electroconvulsive seizures (ECS) induce brain-derived neurotrophic factor (BDNF) expression and sprouting of the mossy fiber pathway in the hippocampus, effects that may be related to electroconvulsive therapy's (ECT) mechanism of action. The objective of this study was to investigate the role of NMDA (N-methyl-D-aspartate) receptor in mediating the ECS-induced mossy fiber sprouting and BDNF expression. Timm histochemistry and in situ hybridization methodologies were used to determine the effect of pretreatment with ketamine, an NMDA antagonist, on ECS-induced sprouting and BDNF expression. The results demonstrate the ability of ketamine pretreatment to attenuate ECS-induced sprouting in the dentate gyrus and BDNF expression in the medial prefrontal cortex and the dentate gyrus. In addition, we found a significant decrease in seizure duration with ketamine pretreatment. These data suggest that NMDA receptor activation contributes to both the regulation of neurotrophic factor expression and the morphological changes associated with seizure activity. However, other effects resulting from shortened seizure duration and seizure intensity cannot be excluded. These findings are of increasing interest, as they relate to the use of ECT in the treatment of depression, and the specific anesthetic agents that are used. © 2001 Lippincott Williams & Wilkins, Inc.